- Home
- OKUR vs SKYE Comparison
OKUR vs SKYE Comparison
Compare OKUR & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKUR
- SKYE
- Stock Information
- Founded
- OKUR 2011
- SKYE 2012
- Country
- OKUR United States
- SKYE United States
- Employees
- OKUR N/A
- SKYE N/A
- Industry
- OKUR
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- OKUR
- SKYE Health Care
- Exchange
- OKUR NYSE
- SKYE Nasdaq
- Market Cap
- OKUR 76.6M
- SKYE 80.7M
- IPO Year
- OKUR N/A
- SKYE N/A
- Fundamental
- Price
- OKUR $2.89
- SKYE $1.44
- Analyst Decision
- OKUR Strong Buy
- SKYE Buy
- Analyst Count
- OKUR 4
- SKYE 6
- Target Price
- OKUR $32.25
- SKYE $16.60
- AVG Volume (30 Days)
- OKUR 49.1K
- SKYE 1.7M
- Earning Date
- OKUR 05-14-2025
- SKYE 05-09-2025
- Dividend Yield
- OKUR N/A
- SKYE N/A
- EPS Growth
- OKUR N/A
- SKYE N/A
- EPS
- OKUR N/A
- SKYE N/A
- Revenue
- OKUR N/A
- SKYE N/A
- Revenue This Year
- OKUR N/A
- SKYE N/A
- Revenue Next Year
- OKUR N/A
- SKYE N/A
- P/E Ratio
- OKUR N/A
- SKYE N/A
- Revenue Growth
- OKUR N/A
- SKYE N/A
- 52 Week Low
- OKUR $2.57
- SKYE $1.14
- 52 Week High
- OKUR $20.00
- SKYE $17.65
- Technical
- Relative Strength Index (RSI)
- OKUR N/A
- SKYE 40.43
- Support Level
- OKUR N/A
- SKYE $1.26
- Resistance Level
- OKUR N/A
- SKYE $3.73
- Average True Range (ATR)
- OKUR 0.00
- SKYE 0.34
- MACD
- OKUR 0.00
- SKYE 0.04
- Stochastic Oscillator
- OKUR 0.00
- SKYE 11.40
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.